ClinicalTrials.gg
CompletedNCT05195775Updated Oct 27, 2026Results posted

Tadalafil as Adjuvant Therapy for DMD

A Phase 2/3 interventional study of Tadalafil in Duchenne Muscular Dystrophy, sponsored by University of Florida. Completed at 1 site in United States. Open to male participants aged 6 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Florida · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now CompletedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
6 Years to 13 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
127th of 172
12 · median 25
Started
2021
with 11 others
Phase 2/3
8 of 233
1 open now
Registered
177th of 233
by date
Lead sponsor
9 of 233
University of Florida

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 127th largest by enrollment of the 172 interventional ones that give a count, is one of 12 that started in 2021, is one of 8 in phase 2/3, and was the 177th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 13 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This project will assess the vascular responsiveness in leg muscles of boys with Duchenne muscular dystrophy (DMD) to one single dose of tadalafil, a common vasodilator drug, using non-invasive techniques (MRI or Doppler ultrasound). These findings will provide proof of concept for a subsequent intervention study to demonstrate efficacy of longer-term tadalafil to counter sympathetic vasoconstriction and slow disease progression in DMD.

Read the detailed description

This project will target up to 25 ambulatory boys with DMD aged 7-30 years. Because the vascular impact of tadalafil is immediate, we will confirm that the drug target is valid target in lower extremities by assessing the change in post-exercise microvascular perfusion using Blood Oxygen Level-Dependent (BOLD) MRI or change in post-exercise hyperemia using Doppler ultrasonography. Patients will be randomized to undergo the above-mentioned assessments with or without the study drug on two separate visits.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • therapy
  • treatment strategy
  • vasodilator
  • exercise
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
6 Years to 13 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of DMD confirmed by 1) clinical history with features before the age of five, 2) physical examination, 3) elevated serum creatine kinase level and 4) absence of dystrophin expression, as determined by immunostaining or Western blot (\<2%) and/or DNA confirmation of dystrophin mutation.
  • Minimum entry age of 7.0 years
  • Ambulatory

Exclusion criteria

Exclusion Criteria:

  • Older than 13.0 years of age
  • to an MR examination (e.g. aneurysm clip, severe claustrophobia, magnetic implants)
  • Presence of unstable medical problems
  • Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease)
  • Contraindications to Tadalafil (use of nitrates, alpha-adrenergic blockers, other phosphodiesterase 5A inhibitors)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Tadalafil plus BOLD-MRI

    This arm will use BOLD-MRI as the technique to monitor drug impact on skeletal muscle.

    Drug: Tadalafil

Interventions

  • Patient will be randomized to one dose of 0.6 mg/kg tadalafil on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.

    Also known as: Cialis

06

What researchers measure

Primary outcomes

  1. Percent Change in Post-contractile BOLD Signal Relative to Resting Condition

    The post contractile blood oxygen level-dependent (BOLD) response is a non-invasive index of microvascular function in muscle using MRI. BOLD images are acquired from the tibialis anterior before and after dorsiflexion exercise. A transient increase in BOLD signal is expected after performing a brief muscle contraction (reflecting increased small vessel oxygen saturation and blood volume). In healthy boys, MRI-BOLD signal was on average 4.4% above resting levels. The greater the value, the more intact the physiological response to muscle contraction. Previous study has reported MRI-BOLD to be on average 2.3% above rest in boys with DMD. We measured the post-contractile BOLD response twice in each participant; once after taking tadalafil (a vasodilator proposed to increase blood flow and microvascular perfusion) and once without taking the tadalafil. The order of assessment was randomized.

    Time frame: MRI will be done 3 hours after dosing/no-dosing on two separate study visits

07

Results

Posted Oct 27, 2026
Limitations and caveats
This was a pilot trial. We did not have any missing data for our pre-specified primary outcome measure.

Participant flow

Period 1 (1 Day)
Participant flow — Period 1 (1 Day)
MilestoneTadalafil Then No InterventionNo Intervention Then Study Drug
Started66
Completed66
Not completed00
Period 2 (1 Day)
Participant flow — Period 2 (1 Day)
MilestoneTadalafil Then No InterventionNo Intervention Then Study Drug
Started66
Completed66
Not completed00

Outcome measures

PrimaryPercent Change in Post-contractile BOLD Signal Relative to Resting Condition

The post contractile blood oxygen level-dependent (BOLD) response is a non-invasive index of microvascular function in muscle using MRI. BOLD images are acquired from the tibialis anterior before and after dorsiflexion exercise. A transient increase in BOLD signal is expected after performing a brief muscle contraction (reflecting increased small vessel oxygen saturation and blood volume). In healthy boys, MRI-BOLD signal was on average 4.4% above resting levels. The greater the value, the more intact the physiological response to muscle contraction. Previous study has reported MRI-BOLD to be on average 2.3% above rest in boys with DMD. We measured the post-contractile BOLD response twice in each participant; once after taking tadalafil (a vasodilator proposed to increase blood flow and microvascular perfusion) and once without taking the tadalafil. The order of assessment was randomized.

Time frame:
MRI will be done 3 hours after dosing/no-dosing on two separate study visits
Reported as:
Mean · percentage of BOLD signal change aseline
Percent Change in Post-contractile BOLD Signal Relative to Resting Condition
percentage of BOLD signal change aselineTadalafil DoseNo Dose
Percent Change in Post-contractile BOLD Signal Relative to Resting Condition3.2 ± 0.92.3 ± 1.4
Statistical analysis
  • Tadalafil Dose · t-test, 2 sided · p = <0.01 (paired t-test) · Mean difference (final values): 0.91The comparison is % change above rest in peak post contractile BOLD signal intensity on tadalafil over % change above rest in peak post contractile BOLD signal intensity without tadalafil.

Adverse events

Collected over Adverse events were collected for 48 hours per patient.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil Visit0/12 (0%)0/12 (0%)5/12 (41.7%)
Placebo Visit0/12 (0%)0/12 (0%)0/12 (0%)
Most frequent other events
Most frequent other events
EventTadalafil VisitPlacebo Visit
HeadacheGeneral disorders5/120/12
Facial flushingSkin and subcutaneous tissue disorders2/120/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BOLD-MRI on and Off Study-drug
<=18 years12
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(Years)BOLD-MRI on and Off Study-drug
Mean9.75 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)BOLD-MRI on and Off Study-drug
Female0
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BOLD-MRI on and Off Study-drug
Hispanic or Latino0
Not Hispanic or Latino11
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BOLD-MRI on and Off Study-drug
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)BOLD-MRI on and Off Study-drug
United States11
Finland1
Weight
Weight(Kg)BOLD-MRI on and Off Study-drug
Mean33.3 ± 8.9
08

Study locations

1 site
  • University of Florida
    Gainesville, Florida 32610, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2021 to primary completion in Apr 2024, 28 months.

Results were first posted in Oct 2026, 2 years 6 months after primary completion.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Apr 2024, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2022
First posted
Jan 19, 2022
StartActual
Dec 14, 2021
Primary completionActual
Apr 16, 2024was Sep 2025
CompletionActual
Sep 8, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Results
Results posted
posted Oct 27, 2026
Primary completion
Sep 5, 2025→Apr 16, 2024 (actual)
Oct 27, 2026
Study completion
Sep 5, 2025→Sep 8, 2025 (actual)
Oct 27, 2026
Enrollment
25 (estimated)→12 (actual)
Oct 27, 2026
Eligibility
Minimum age 7 Years→6 Years; 1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedContraindications to Tadalafil (use of nitrates, alpha-adrenergic blockers, other PDE5Aphosphodiesterase 5A inhibitors)
Oct 27, 2026
Interventions
Removed Drug: Tadalafil. Arm changed Tadalafil plus BOLD-MRI (Schedule A)→Tadalafil plus BOLD-MRI. Arms removed: Tadalafil plus Doppler ultrasound (Schedule B)
Oct 27, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedPercent Change in postPost-contractile BOLD response after tadalafil dosingSignal Relative to Resting ConditionTime frame: MRI will be done 3 hours after dosing/no-dosing on two separate study visits
  • RemovedChange in post-exercise hyperemia after tadalafil dosingTime frame: Doppler ultrasound will be done 3 hours after dosing/no-dosing on two separate study visits
Oct 27, 2026
Documents
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedChange in submaximal exercise capacity after tadalafil dosingTime frame: Cycle testing will be done 4 hours after dosing/no-dosing on two separate study visits
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Sep 5, 2025→Apr 16, 2024 (now actual)
    Study completion Sep 5, 2025→Sep 8, 2025 (now actual)
    Enrollment 25 (estimated)→12 (actual)
    Eligibility Minimum age 7 Years→6 Years; 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedContraindications to Tadalafil (use of nitrates, alpha-adrenergic blockers, other PDE5Aphosphodiesterase 5A inhibitors)
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedPercent Change in postPost-contractile BOLD response after tadalafil dosingSignal Relative to Resting ConditionTime frame: MRI will be done 3 hours after dosing/no-dosing on two separate study visits
    • RemovedChange in post-exercise hyperemia after tadalafil dosingTime frame: Doppler ultrasound will be done 3 hours after dosing/no-dosing on two separate study visits
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedChange in submaximal exercise capacity after tadalafil dosingTime frame: Cycle testing will be done 4 hours after dosing/no-dosing on two separate study visits
    Interventions Removed Drug: Tadalafil. Arm changed Tadalafil plus BOLD-MRI (Schedule A)→Tadalafil plus BOLD-MRI. Arms removed: Tadalafil plus Doppler ultrasound (Schedule B)
    + 3 other changes: description, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05195775
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Dec 14, 2021
Primary completion
Apr 16, 2024
Completion
Sep 8, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Tanja Taivassalo
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion